L‑carnitine ameliorates the liver inflammatory response by regulating carnitine palmitoyltransferase I‑dependent PPARγ signaling

Jiang,Fang; Zhang,Zongqi; Zhang,Yi; Wu,Jianping; Yu,Li; Liu,Su

doi:10.3892/mmr.2015.4639

L‑carnitine ameliorates the liver inflammatory response by regulating carnitine palmitoyltransferase I‑dependent PPARγ signaling

Authors:
- Fang Jiang
- Zongqi Zhang
- Yi Zhang
- Jianping Wu
- Li Yu
- Su Liu
View Affiliations

Affiliations: Department of Gastroenterology, Zhabei District Central Hospital, Shanghai 200070, P.R. China, Department of Cardiology, No. 3 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201900, P.R. China, Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China
Published online on: December 4, 2015 https://doi.org/10.3892/mmr.2015.4639
Pages: 1320-1328

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The liver is crucial for systemic inflammation in cancer cachexia. Previous studies have shown that L‑carnitine, as the key regulator of lipid metabolism, exerts an anti‑inflammatory effect in several diseases, and ameliorates the symptoms of cachexia by regulating the expression and activity of carnitine palmitoyltransferase (CPT) in the liver. However, the effect of L‑carnitine on the liver inflammatory response in cancer cachexia remains to be elucidated. The aim of the present study was to examine the role of the CPT I‑dependent peroxisome proliferator‑activated receptor (PPAR)γ signaling pathway in the ameliorative effect of L‑carnitine on the liver inflammatory response. This was investigated in a colon‑26 tumor‑bearing mouse model with cancer cachexia. Liver sections were immunohistochemically analyzed, and mRNA and protein levels of representative molecules of the CPT-associated PPARγ signaling pathway were assessed using PCR and western blot analysis, respectively. The results showed that oral administration of L‑carnitine in these mice improved hepatocyte necrosis, liver cell cord derangement and hydropic or fatty degeneration of the liver cells in the liver tissues, decreased serum levels of malondialdehyde, increased serum levels of superoxide dismutase and glutathione peroxidase, and elevated the expression levels of PPARα and PPARγ at the mRNA and protein levels. These changes induced by L‑carnitine were reversed by treatment with etomoxir, an inhibitor of CPT I. The inhibitory effect of L‑carnitine on the increased expression level of nuclear factor (NF)‑κB p65 in the peripheral blood mononuclear cells was markedly weakened by GW9662, a selective inhibitor of PPAR‑γ. GW9662 also eliminated the inhibitory effect of L‑carnitine on the expression of cyclooxygenase‑2 (Cox‑2) in the liver, and on the serum expression levels of pro‑inflammatory prostaglandin E2, C-reactive protein, tumor necrosis factor‑α and interleukin‑6 in the cancer cachexia model mice. This reversing effect of GW9662 on L‑carnitine was restored by pyrrolidine dithiocarbamate, a specific inhibitor of NF‑κB signaling. Taken together, these results demonstrated that L‑carnitine ameliorated liver inflammation and serum pro‑inflammatory markers in cancer cachexia through regulating CPT I‑dependent PPARγ signaling, including the downstream molecules of NF‑κB p65 and Cox‑2.

View Figures

View References

1	Trutschnigg B, Kilgour RD, Morais JA, Lucar E, Hornby L, Molla H and Vigano A: Metabolic, nutritional and inflammatory characteristics in elderly women with advanced cancer. J Geriatr Oncol. 4:183–189. 2013. View Article : Google Scholar : PubMed/NCBI
2	Richards CH, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, Guthrie GK, Horgan PG and McMillan DC: The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One. 7:e418832012. View Article : Google Scholar : PubMed/NCBI
3	Liu S, Wu HJ, Zhang ZQ, Chen Q, Liu B, Wu JP and Zhu L: L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase. Cancer Biol Ther. 12:125–130. 2011. View Article : Google Scholar : PubMed/NCBI
4	Jiang Y, Guo C, Zhang D, Zhang J, Wang X and Geng C: The altered tight junctions: An important gateway of bacterial translocation in cachexia patients with advanced gastric cancer. J Interferon Cytokine Res. 34:518–525. 2014. View Article : Google Scholar : PubMed/NCBI
5	Wang LH, Yang XY, Mihalic K, Xiao W, Li D and Farrar WL: Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J Biol Chem. 276:31839–31844. 2001. View Article : Google Scholar : PubMed/NCBI
6	Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG and Zimmers TA: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 6:e225382011. View Article : Google Scholar : PubMed/NCBI
7	Martignoni ME, Dimitriu C, Bachmann J, Krakowski-Rosen H, Ketterer K, Kinscherf R and Friess H: Liver macrophages contribute to pancreatic cancer-related cachexia. Oncol Rep. 21:363–369. 2009.PubMed/NCBI
8	Watchorn TM, Dowidar N, Dejong CH, Waddell ID, Garden OJ and Ross JA: The cachectic mediator proteolysis inducing factor activates NF-kappaB and STAT3 in human Kupffer cells and monocytes. Int J Oncol. 27:1105–1111. 2005.PubMed/NCBI
9	Wang W, Andersson M, Lõnnroth C, Svanberg E and Lundholm K: Prostaglandin E and prostacyclin receptor expression in tumor and host tissues from MCG 101-bearing mice: A model with prostanoid-related cachexia. Int J Cancer. 115:582–590. 2005. View Article : Google Scholar : PubMed/NCBI
10	Mantovani G, Macciò A, Madeddu C, Serpe R, Antoni G, Massa E, Dessì M and Panzone F: Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl). 88:85–92. 2010. View Article : Google Scholar
11	Sue YM, Chou HC, Chang CC, Yang NJ, Chou Y and Juan SH: L-carnitine protects against carboplatin-mediated renal injury: AMPK- and PPARα-dependent inactivation of NFAT3. PLoS One. 9:e1040792014. View Article : Google Scholar
12	Ishikawa H, Takaki A, Tsuzaki R, Yasunaka T, Koike K, Shimomura Y, Seki H, Matsushita H, Miyake Y, Ikeda F, et al: L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway. PLoS One. 9:e1006272014. View Article : Google Scholar : PubMed/NCBI
13	Demiroren K, Dogan Y, Kocamaz H, Ozercan IH, Ilhan S, Ustundag B and Bahcecioglu IH: Protective effects of L-carnitine, N-acetylcysteine and genistein in an experimental model of liver fibrosis. Clin Res Hepatol Gastroenterol. 38:63–72. 2014. View Article : Google Scholar
14	Vinci E, Rampello E, Zanoli L, Oreste G, Pistone G and Malaguarnera M: Serum carnitine levels in patients with tumoral cachexia. Eur J Intern Med. 16:419–423. 2005. View Article : Google Scholar : PubMed/NCBI
15	Breitkreutz R, Babylon A, Hack V, Schuster K, Tokus M, Böhles H, Hagmüller E, Edler L, Holm E and Dröge W: Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases. Br J Cancer. 82:399–403. 2000. View Article : Google Scholar : PubMed/NCBI
16	Khan SA, Ali A, Khan SA, Zahran SA, Damanhouri G, Azhar E and Qadri I: Unraveling the complex relationship triad between lipids, obesity and inflammation. Mediators Inflamm. 2014:5027492014. View Article : Google Scholar
17	Silverio R, Laviano A, Rossi Fanelli F and Seelaender M: L-Carnitine induces recovery of liver lipid metabolism in cancer cachexia. Amino Acids. 42:1783–1792. 2012. View Article : Google Scholar
18	Zambrano S, Blanca AJ, Ruiz-Armenta MV, Miguel-Carrasco JL, Arévalo M, Vázquez MJ, Mate A and Vázquez CM: L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. Biochem Pharmacol. 85:937–944. 2013. View Article : Google Scholar : PubMed/NCBI
19	El-Sheikh AA and Rifaai RA: Peroxisome proliferator activator receptor (PPAR)-γ ligand, but Not PPAR-α, ameliorates cyclophosphamide-induced oxidative stress and inflammation in rat liver. PPAR Res. 2014:6263192014. View Article : Google Scholar
20	Chen K, Li J, Wang J, Xia Y, Dai W, Wang F, Shen M, Cheng P, Zhang Y, Wang C, et al: 15-Deoxy-γ 12,14-prostaglandin J2 reduces liver impairment in a model of ConA-induced acute hepatic inflammation by activation of PPAR γ and Reduction in NF-κB Activity. PPAR Res. 2014:2156312014.
21	Song S, Attia RR, Connaughton S, Niesen MI, Ness GC, Elam MB, Hori RT, Cook GA and Park EA: Peroxisome prolif-erator activated receptor alpha (PPARalpha) and PPARgamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements. Mol Cell Endocrinol. 325:54–63. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kashinakunti SV, Kollur P, Kallaganada GS, Rangappa M and Ingin JB: Comparative study of serum MDA and vitamin C levels in non-smokers, chronic smokers and chronic smokers with acute myocardial infarction in men. J Res Med Sci. 16:993–998. 2011.
23	Hübscher SG: Histological assessment of non-alcoholic fatty liver disease. Histopathology. 49:450–465. 2006. View Article : Google Scholar : PubMed/NCBI
24	Jia XL, Li SY, Dang SS, Cheng YA, Zhang X, Wang WJ, Hughes CE and Caterson B: Increased expression of chondroitin sulphate proteoglycans in rat hepatocellular carcinoma tissues. World J Gastroenterol. 18:3962–3976. 2012. View Article : Google Scholar : PubMed/NCBI
25	Tisdale MJ: Mechanisms of cancer cachexia. Physiol Rev. 89:381–410. 2009. View Article : Google Scholar : PubMed/NCBI
26	Luna G, Florence L and Johansen K: Hepatocellular carcinoma. A 5 year institutional experience. Am J Surg. 149:591–594. 1985. View Article : Google Scholar : PubMed/NCBI
27	Barreiro E, de la Puente B, Busquets S, López-Soriano FJ, Gea J and Argiles JM: Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett. 579:1646–1652. 2005. View Article : Google Scholar : PubMed/NCBI
28	Zeng T, Zhang CL, Song FY, Zhao XL and Xie KQ: CMZ reversed chronic ethanol-induced disturbance of PPAR-α possibly by suppressing oxidative stress and PGC-1α acetylation and activating the MAPK and GSK3β pathway. PLoS One. 9:e986582014. View Article : Google Scholar
29	Al Rouq F and El Eter E: PPAR-γ activator induces neuropro-tection in hypercholesterolemic rats subjected to global cerebral ischemia/reperfusion injury: In vivo and in vitro inhibition of oxidative stress. Exp Gerontol. 51:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
30	Moore-Carrasco R, Figueras M, Ametller E, López-Soriano FJ, Argilés JM and Busquets S: Effects of the PPARgamma agonist GW1929 on muscle wasting in tumour-bearing mice. Oncol Rep. 19:253–256. 2008.
31	Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB and Spiegelman BM: Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell. 8:971–982. 2001. View Article : Google Scholar : PubMed/NCBI
32	Asp Ml, Tian M, Kliewer KL and Belury MA: Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia. Cancer Biol Ther. 12:957–965. 2011. View Article : Google Scholar : PubMed/NCBI
33	Huang J, Das SK, Jha P, Al Zoughbi W, Schauer S, Claudel T, Sexl V, Vesely P, Birner-Gruenberger R, Kratky D, et al: The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. Biochim Biophys Acta. 1831:1555–1565. 2013. View Article : Google Scholar : PubMed/NCBI
34	Yuan K, Huang C, Fox J, Gaid M, Weaver A, Li G, Singh BB, Gao H and Wu M: Elevated inflammatory response in caveolin-1-deficient mice with Pseudomonas aeruginosa infection is mediated by STAT3 protein and nuclear factor kappaB (NF-kappaB). J Biol Chem. 286:21814–21825. 2011. View Article : Google Scholar : PubMed/NCBI
35	Zhou W, Jiang ZW, Tian J, Jiang J, Li N and Li JS: Role of NF-kappaB and cytokine in experimental cancer cachexia. World J Gastroenterol. 9:1567–1570. 2003. View Article : Google Scholar : PubMed/NCBI
36	Li CC, Yang HT, Hou YC, Chiu YS and Chiu WC: Dietary fish oil reduces systemic inflammation and ameliorates sepsis-induced liver injury by up-regulating the peroxisome proliferator-activated receptor gamma-mediated pathway in septic mice. J Nutr Biochem. 25:19–25. 2014. View Article : Google Scholar
37	Zuniga J, Cancino M, Medina F, Varela P, Vargas R, Tapia G, Videla LA and Fernández V: N-3 PUFA supplementation triggers PPAR-α activation and PPAR-alpha/NF-κB interaction: Anti-inflammatory implications in liver ischemia-reperfusion injury. PLoS One. 6:e285022011. View Article : Google Scholar
38	Ozturk H, Gezici A and Ozturk H: The effect of celecoxib, a selective COX-2 inhibitor, on liver ischemia/reperfusion-induced oxidative stress in rats. Hepatol Res. 34:76–83. 2006. View Article : Google Scholar
39	Onesti JK and Guttridge DC: Inflammation based regulation of cancer cachexia. Biomed Res Int. 2014:1684072014. View Article : Google Scholar : PubMed/NCBI
40	Cossette E, Cloutier I, Tardif K, DonPierre G and Tanguay JF: Estradiol inhibits vascular endothelial cells pro-inflammatory activation induced by C-reactive protein. Mol Cell Biochem. 373:137–147. 2013. View Article : Google Scholar :
41	White JP, Baltgalvis KA, Puppa MJ, Sato S, Baynes JW and Carson JA: Muscle oxidative capacity during IL-6-dependent cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 300:R201–R211. 2011. View Article : Google Scholar :
42	Remels AH, Gosker HR, Langen RC and Schols AM: The mechanisms of cachexia underlying muscle dysfunction in COPD. J Appl Physiol (1985). 114:1253–1262. 2013. View Article : Google Scholar